Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: Reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan

Rector, Thomas S.; Cohn, Jay N.

doi:10.1016/0002-8703(92)90986-6

Cited by 895 publications

(647 citation statements)

References 14 publications

Supporting

Mentioning

608

Contrasting

Unclassified

Order By: Relevance

“…The questionnaire measures the self-perception of well-being in physical and emotional dimensions in patients with chronic heart failure. The physical dimension is closely related to physical capacity, so that the higher the score of well being, the lower the physical status 16 . Not surprisingly, therefore, in patients with Chagas-SAH, a similar negative correlation was determined between well-being selfperception and physical capacity, as detected by the 6MWT.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of the six-minute walk test in patients with chronic heart failure associated with Chagas' disease and systemic arterial hypertension

Dourado

Bestetti

Cardinalli-Neto

et al. 2010

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

INTRODUCTION: To evaluate physical capacity as determined by the six-minute walk test (6MWT) in patients with chronic heart failure due to Chagas' disease associated with systemic arterial hypertension (Chagas-SAH). METHODS: A total of 98 patients routinely followed at the Cardiomyopathy Outpatient Service were recruited. Of these, 60 (61%) were diagnosed with Chagas disease and 38 (39%) with Chagas-SAH. RESULTS: The distance walked during 6 min was 357.9 ±98 m for Chagas-SAH patients and 395.8 ± 121m for Chagas cardiomyopathy patients (p >0.05). In patients with Chagas-SAH, a negative correlation occurred between the 6MWT and the total score of the Minnesota Living with Heart Failure Questionnaire (r= -0.51; p=0.001). No other correlations were determined between 6MWT values and continuous variables in patients with Chagas-SAH. CONCLUSIONS: The results of the 6MWT in Chagas-SAH patients are similar to those verified in Chagas cardiomyopathy patients with chronic heart failure. Coexistence of SAH does not seem to affect the functional capacity of Chagas cardiomyopathy patients with chronic heart failure.

show abstract

Section: Discussionmentioning

confidence: 99%

“…The daily dose of each drug was that taken at the time of the 6MWT performance. All patients also replied to the Minnesota Living with Heart Failure Questionnaire (MLWHFQ) 16 , as previously described 17 .…”

Section: Patientsmentioning

confidence: 99%

Evaluation of the six-minute walk test in patients with chronic heart failure associated with Chagas' disease and systemic arterial hypertension

Dourado

Bestetti

Cardinalli-Neto

et al. 2010

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

show abstract

“…27 . Patients hospitalized (heart failure), n (%) 10 (11) 17 (19) Number of hospitalizations (heart failure) 16 22 Duration of hospitalization for heart failure, median (IQR) 9 (7-33) 17 (8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25) 0.62…”

Section: Limitationsmentioning

confidence: 99%

A randomized trial of home telemonitoring in a typical elderly heart failure population in North West London: results of the Home‐HF study

Dar

Riley

Chapman

et al. 2009

European J of Heart Fail

124

217

View full text Add to dashboard Cite

Aims Heart failure chiefly affects the elderly, with frequent emergency admissions. Telemonitoring can identify worsening heart failure but previous randomized trials have enrolled selected patient populations. The Home‐HF study examined the impact of home telemonitoring on typical heart failure patients discharged from three acute hospitals in North West London, UK. Methods and results Patients hospitalized with heart failure were randomized to telemonitoring or usual specialist care. Primary outcome measures were days alive and out of hospital. Secondary outcome measures were number and duration of heart failure hospitalizations, clinic visits, and quality of life. We recruited 182 patients. There was no difference in the primary outcome measure in the two groups, but there were significantly fewer unplanned hospitalizations for heart failure decompensation, and a reduction in clinic and emergency room visits in the telemonitoring group. There was no statistically significant difference in the mean direct health service costs. Conclusion Home telemonitoring in a typical elderly population of heart failure patients produces a similar outcome to ‘usual’ specialist care, but reduces clinic and emergency room visits and unplanned heart failure rehospitalizations at little additional cost. This method of disease monitoring may allow specialist services to increase the number of patients under their care.

show abstract

“…• Minnesota living with heart failure questionnaire [21] • Changes in parameters related to LV diastolic function, including peak E velocity at the Doppler recording of transmitral inflow tracing, peak E 0 velocity of the mitral valve annulus measured at the level of the septal and lateral wall, respectively, by tissue Doppler recording, and the E/E 0 ratio.…”

Section: Endpointsmentioning

confidence: 99%

Effect of the long-term administration of nebivolol on clinical symptoms, exercise capacity and left ventricular function in patients with heart failure and preserved left ventricular ejection fraction: background, aims and design of the ELANDD study

et al. 2009

View full text Add to dashboard Cite

Background The SENIORS trial demonstrated that nebivolol has beneficial effects in patients with heart failure. However, the role of beta-blocker therapy in patients with heart failure and preserved left ventricular ejection fraction (HFPEF) is still unsettled. Objective To assess the long-term effects of administration of nebivolol, compared to placebo, on the clinical symptoms, exercise capacity and parameters of left ventricular (LV) function in patients with HFPEF. Methods The Effect of Long-term Administration of Nebivolol on clinical symptoms, exercise capacity and left ventricular function in patients with Diastolic Dysfunction (ELANDD) study is a prospective multicenter European trial in 120 patients with HFPEF randomised to nebivolol or placebo. HFPEF is defined as symptoms or signs of heart failure, a LV ejection fraction [45% and evidence of diastolic LV dysfunction by Doppler echocardiography. Procedures include a baseline clinical examination, 6-min walk test (6MWT), electrocardiography, Doppler echocardiography and Minnesota QoL questionnaire. Nebivolol or placebo is started at 2.5 mg/day and gradually uptitrated to 10 mg/day. After initiation of the study, patients are assessed at 1, 2, 5 and 6 weeks (titration phase) and at weeks 12 and 26. The primary endpoint is the change from baseline in the 6MWT distance with nebivolol versus placebo. Sample size calculations are based on an anticipated 15% difference (70 m) in the 6MWT distance between nebivolol and placebo-treated patients. This study will allow the collection of data regarding the possible For the ELANDD investigators.

show abstract

Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: Reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan

Cited by 895 publications

References 14 publications

Evaluation of the six-minute walk test in patients with chronic heart failure associated with Chagas' disease and systemic arterial hypertension

Evaluation of the six-minute walk test in patients with chronic heart failure associated with Chagas' disease and systemic arterial hypertension

A randomized trial of home telemonitoring in a typical elderly heart failure population in North West London: results of the Home‐HF study

Effect of the long-term administration of nebivolol on clinical symptoms, exercise capacity and left ventricular function in patients with heart failure and preserved left ventricular ejection fraction: background, aims and design of the ELANDD study

Contact Info

Product

Resources

About